Our Team
Office
Tel
Education
Admissions & Qualifications
Associate
Jeffrey Hang
Jeffrey Hang is an associate in the Hong Kong office of Edwin Kwok & Co, and a key member of the Corporate Finance and Capital Markets practice group. His expertise spans advising clients on digital finance, virtual currencies, Web3.0, artificial intelligence (AI), as well as Hong Kong IPO, mergers and acquisitions (M&A), regulatory compliance, and general corporate matters.
Experience
Technology:
- Advised on the setup of an online wine platform that utilizes tokenization and Web3.0 technology, focusing on transaction
- workflow, regulatory and legal advice and UX design.
- Advised on Artificial Intelligence Association of Hong Kong.
M&A:
- Advised a prominent e-commerce platform with its US$375 million equity investment in a leading e-payment and e-wallet
- company in Indonesia.
- Advised a sovereign wealth fund in connection with its US$400 million note financing to an AR company.
- Advised a cell therapy company in its US$15.5million series A-1 financing, including a convertible bond conversion.
- Represented a sovereign wealth fund in connection with two separate investments totalling US$500 million in operators of luxury hospitality resorts.
- Advised one of the largest construction managers in its strategic acquisition of the Hong Kong and Singapore branches of a leading design and engineering consultancy firm.
- Represented Central China Real Estate (SEHK:832) and its controlling shareholder in its US$83 million share sale.
Capital Market:
IPO Sponsor Side:
- Listed: (1) Qyuns Therapeutics Co Ltd (SEHK:2509, for CICC); (2) Huafang Group Inc. (SEHK:3611, for Haitong and CCBI); (3) Shanghai Voicecomm Information Technology Co., Ltd. (SEHK:2495, for CICC); (4) Lushang Life Service Co., Ltd. (SEHK:2376, for ABCI).
- Pre-A1 submission and/or A1 application stage: (1) a digital insurance platform (for CICC and Huatai); (2) a digital health management company (for CICC and ABCI); (3) an AI service developer (for Haitong and CSCI); (4) a beer manufacturer (for BofA and CICC); (5) a genomic testing company (for China Merchant Securities); (6) an 18A implantable minimally invasive medical device company (for Citi and Huatai); (7) vascular intervention device company (for Credit Suisse and Citi); (8) a property developer (for CCBI).
IPO Issuer Side:
- Listed: (1) OrbusNeich Medical Group Holdings Limited (SEHK:6929); (2) Jenscare Scientific Co., Ltd. (SEHK:9877); (3) Rainmed Medical Limited (SEHK:2297); (4) Ruichang International Holdings (SEHK:1334).
- Pre-A1 submission and/or A1 application stage: (1) a cloud computing and data centre company; (2) a waste treatment company; (3) a peptide manufacturer.
Dispute Resolution:
- Involved in the recovering of assets from a bankrupted politically-sensitive individual for an investment company in US and Hong Kong.
- Defended a CBD company related to custom charges and conducted relevant legal research.
- Defended an investment fund in interim injunction proceedings in Hong Kong and its arbitration in London.
- Represented an investment fund in a Hong Kong court action regarding fraud and misuse of funds.
*including experience from previous firms.
